As Pfizer’s Chief Patient Officer, Dr. Freda Lewis-Hall’s vision of patient-centricity is to serve patients around the world by seeking their voice and input, as well as understanding and responding to their needs. Biopharmaceutical companies can leverage its their resources to put patients first by advocating on behalf of patients who are counting on the delivery of innovative medicines and vaccines. To fulfill this mission, Dr. Lewis-Hall takes a multi-pronged approach, which centers on the following principles:
- Deepen insight into patient needs to ensure that the patient voice is thoroughly embedded in research and development
- Target gender, age, and race inequities in our health system to help patients’ access medicines
- Extend the reach of health information and education initiatives to improve public health literacy
- Galvanize thousands of employees to become individual ‘Chief Patient Officers’ in their own right
Executive Vice President and Chief Patient Officer
Health care stakeholders are in the midst of radical change, with a shift to value-based care and an increase in stakeholder consolidations and acquisitions. In addition to increased vertical integration, other disruptors are moving into health care, such as Amazon with its vision to reshape the way prescription drugs are delivered. Yet, amidst all of this change, these constants remain: organizations must focus managing costs, improving quality of care, and enhancing the patient experience. For pharmaceutical companies to ensure patients are at the center of their organization’s strategy, they must understand and adapt to this changing marketplace, meet the needs of their customers in the move to value-based care, be a valued partner in ensuring care coordination and improved patient experiences.
- Explore current merger and acquisition trends to adjust care delivery and payment strategies
- Identify changing stakeholder needs and incentives when developing partnerships with payers, providers, PBMs, and advocacy groups
- Examine how changes in health care delivery are creating new opportunities for collaboration to improve patient outcomes
Chief Medical Officer
Chief Executive Officer
National Coalition on HealthCare
Vice President, Patient Engagement & Chief Experience Officer
Holy Name Medical Center
In July 2018, CMS released a memo to Medicare Part D plans explaining CMS’s expectations regarding formulary exception requests. The memo also provided tools to plans to ensure that beneficiaries utilize low-cost generics when available on formulary and designed drug dashboards to ensure drug pricing transparency. As CMS continues to move health care toward greater implementation of value-based care and patient affordability, stakeholders must align organizational strategies to focus on quality. Explore recent changes to Medicare Part D, population health initiatives, and future CMS priorities for value-based care.
- Gain a high-level overview of the recently release Medicare Part D changes
- Learn about CMS efforts to improve population health and quality of care
- Discuss the implications of future CMS priorities on all stakeholders
Chief Medical Officer
Office of the Regional Administrator, Centers for Medicare and Medicaid Services
Patients and caregivers can deliver insights that are crucial to the advancement of new therapies, market access, patient advocacy, and adherence. It is critical to map the patient journey to overcome roadblocks faced along the continuum of care. Ensuring patient-centricity isn’t just a buzzword requires manufacturers and key stakeholders to put themselves in the shoes of their patients. Hear directly from patients about their experiences with commercial and rare disease therapies, how they navigate the health care system, and where opportunities exist to elevate the patient voice within your organization’s strategies.
- Gain insight into the real-life struggles of patients and caregivers
- Explore best practices when implementing patient support services
- Understand how to build interventions that improve adherence, foster advocacy collaborations, and advance market access
Executive Director, Board Chairman, American Living Organ Donor Fund;
Patient Advisor, PCORI Ambassador;
The market access, pricing, and reimbursement landscape is rapidly evolving as stakeholders shift to a value-based health care system. The high price of some pharmaceuticals has made it difficult for patients to afford and access their medications, increasing the likelihood of non-adherence, discontinuation of therapy, and soaring out-of-pocket costs. Health plans and PBMs are using utilization management practices such as prior authorizations or step therapy to manage the cost of drugs to the system. At the same time, co-pay assistance and other patient support programs are used to help make prescriptions more affordable to patients. In order to improve the patient experience, stakeholders must collaborate and develop strategies to ensure patient access and overcome affordability challenges.
- Understand how to design effective patient access and assistance programs
- Discuss the implications of copay and coupon use on patient access
- Gain insight into patient decision making to identify where opportunities to provide additional support may exist
- Discuss ways stakeholders can improve collaboration to ensure access to necessary medicines
Promidian, an EVERSANA company
The latest public policies, trends across the industry, and organizational shifts shape the way that advocacy teams must look at their strategic initiatives. In this panel, assess the current and future landscape of patient advocacy to help define your organization’s strategy and align internal teams to support patient needs and corporate goals.
- Explore the current trends and future market shifts impacting patient advocacy and policy initiatives
- Incorporate the patient voice throughout the product lifecycle to define a patient-centric patient advocacy strategy
- Define the role of advocacy in translating the patient experience to functions across the company
- Align advocacy priorities with internal corporate strategy, marketing, public relations, and clinical research to achieve targets and support patients
Both pharmaceutical companies and patient advocacy groups have a shared interest in improving the lives of patients. Pharmaceutical companies have extensive scientific knowledge, resources, and experience to share with patient groups. Patient groups provide an inside perspective of the patient journey and patient perspectives that can help companies develop patient-centric solutions. Together, patient advocacy groups and pharmaceutical companies can improve clinical trial design, create better awareness of diseases, and improve the quality of care for patients. With patient advocacy groups taking an active role in both policy and scientific research, pharmaceutical companies can develop collaborations that ensure the patient voice is incorporated across the entire product development cycle. Hear what patient advocacy groups deem as a “valuable” within their relationships with manufacturers and how to best develop long-lasting partnerships that ensure the patient voice is heard.
- Learn how to build partnerships with patient advocates, create bilateral relationships with patient advocacy organizations, and empower patient representation within your organization
- Create mutually beneficial partnerships with advocacy groups to better educate patients and caregivers about diseases and health issues
- Understand how pharmaceutical companies can encourage patient group independence in industry-patient group relations
- Examine ways to define goals for advocacy collaboration in public policy and engagement initiatives
- Incorporate patient group values into partnerships and collaboration strategies
In order to secure more resources dedicated to patient advocacy, manufacturers must demonstrate the value of patient advocacy initiatives. Traditional models of measurement such as those used in sales do not apply in measuring advocacy success. This makes it difficult to develop metrics that represent a tangible benefit for the resources devoted to patient advocacy efforts. In order to achieve success, manufacturers must set key performance indicators, metrics, and processes to measure the success of advocacy in improving patient outcomes.
- Develop metrics to monitor engagement and demonstrate the value of advocacy initiatives
- Create key performance indicators to quantify success
- Leverage data to measure the impact of advocacy programs
Vice president, Patient Engagement, Edwards Lifesciences
Adjunct Faculty, Georgetown University
Involving the patient voice in all aspects of drug development is an ongoing priority for the FDA. As the FDA continues to roll out patient representation and engagement initiatives, there is opportunity for manufacturers, advocacy groups, and government executives to collaborate on effective ways to engage patients. Gain insight into recent FDA initiatives to include the patient voice in various aspects of drug development, including the patient-focused drug development guidance series, and opportunities for patient stakeholders to engage with FDA.
- Understand why patient engagement is important to the regulatory decision making process
- Discover FDA initiatives to drive patient engagement and patient-focused drug development
- Discuss current FDA programs and future initiatives around policy efforts related to patient engagement
- Gain clarity on how to effectively engage patient groups in co-creating solutions
- Use patient engagement to enhance product development